View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
  • 2 Magyar Tudományos Akadémia Molekuláris Medicina Kutatócsoport Budapest

A hepatocellularis carcinoma kórjóslata rossz. A felismeréskor a betegek 85%-a nem alkalmas a kuratív kezelésre, ezekben az esetekben a palliatív módozatok, a transarterialis kemoembolisatio, a rádiófrekvenciás ablatio és a szisztémás kemoterápia alkalmazhatóak. A szisztémás kemoterápia eredményei kiábrándítóak. Molekuláris biológiai ismereteink a célzott kezelési lehetőségek tárát bővíthetik a jövőben. Jelenleg a multikinázgátló sorafenib van csak törzskönyvezve hazánkban, de ígéretesek lehetnek még a VEGF-gátlók (bevacizumab, sunitinib), az EGFR-útvonal gátlása (erlotinib), valamint az mTOR-gátlók (rapamycin és származékai). Előnyös lehet a sorafenib vagy más érképződést gátló együttes adása helyi ablatív eljárásokkal (transarterialis kemoembolisatio, rádiófrekvenciás ablatio) vagy kuratív hepatectomiával. A jövő további lehetőségei közé tartoznak a Wnt-útvonalat módosítók, a retinoid vegyületek, a sejtciklusgátlók, a proteoszómagátlók és az epigenetikus kezelés. Orv. Hetil., 2010, 43, 1763–1768.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Parikh, S., Hyman, D.: Hepatocellular cancer: A guide for the internist. Am. J. Med., 2007, 120 , 194–202.

    Hyman D. , 'Hepatocellular cancer: A guide for the internist ' (2007 ) 120 Am. J. Med. : 194 -202.

    • Search Google Scholar
  • El-Serag, H. B., Lenhard, R.: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132 , 2557–2576.

    Lenhard R. , 'Hepatocellular carcinoma: epidemiology and molecular carcinogenesis ' (2007 ) 132 Gastroenterology : 2557 -2576.

    • Search Google Scholar
  • Farazi, P. A., DePinho, R. A.: Hepatocellular carcinoma pathogenesis from genes to environment. Nature Rev. Cancers, 2006, 6 , 674–687.

    DePinho R. A. , 'Hepatocellular carcinoma pathogenesis from genes to environment ' (2006 ) 6 Nature Rev. Cancers : 674 -687.

    • Search Google Scholar
  • Aravalli, R. N., Steer, C. J., Cresman, E. N. K.: Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008, 48 , 2047–2063.

    Cresman E. N. K. , 'Molecular mechanisms of hepatocellular carcinoma ' (2008 ) 48 Hepatology : 2047 -2063.

    • Search Google Scholar
  • Okuda, H.: Hepatocellular carcinoma development in cirrhosis. Best Practice Res. Clin. Gastroenterol., 2007, 21 , 161–173.

    Okuda H. , 'Hepatocellular carcinoma development in cirrhosis ' (2007 ) 21 Best Practice Res. Clin. Gastroenterol. : 161 -173.

    • Search Google Scholar
  • Pang, R., Tse, E., Poon, R. T. P.: Molecular pathways in hepatocellular carcinoma. Cancer Letters, 2006, 240 , 157–169.

    Poon R. T. P. , 'Molecular pathways in hepatocellular carcinoma ' (2006 ) 240 Cancer Letters : 157 -169.

    • Search Google Scholar
  • Llovet, J. M., Bruix, J.: Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol., 2008, 48 , S20–S37.

    Bruix J. , 'Novel advancements in the management of hepatocellular carcinoma in 2008 ' (2008 ) 48 J. Hepatol. : S20 -S37.

    • Search Google Scholar
  • Nagy P., László V., Schaff Zs.: A hepatokarcinogenezis folyamata human májban. Magyar Onkológia, 2006, 50 , 107–113.

    Schaff Zs. , 'A hepatokarcinogenezis folyamata human májban ' (2006 ) 50 Magyar Onkológia : 107 -113.

    • Search Google Scholar
  • Zhu, J.: DNA methylation and hepatocellular carcinoma. J. Hepato-Biliary-Pancreatic Surgery, 2006, 13 , 265–273.

    Zhu J. , 'DNA methylation and hepatocellular carcinoma ' (2006 ) 13 J. Hepato-Biliary-Pancreatic Surgery : 265 -273.

    • Search Google Scholar
  • Hagymási K., Tulassay Zs.: Az elsődleges májrák epidemiológiája, kóroka és kialakulásának molekuláris háttere. Orv. Hetil., 2008, 149 , 541–548.

    Tulassay Zs. , 'Az elsődleges májrák epidemiológiája, kóroka és kialakulásának molekuláris háttere ' (2008 ) 149 Orv. Hetil. : 541 -548.

    • Search Google Scholar
  • Breuhahn, K., Longerich, T., Schimacher, P.: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 2006, 25 , 3787–3800.

    Schimacher P. , 'Dysregulation of growth factor signaling in human hepatocellular carcinoma ' (2006 ) 25 Oncogene : 3787 -3800.

    • Search Google Scholar
  • Fabregat, I., Roncero, C., Fernández, M.: Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int., 2007, 27 , 155–162.

    Fernández M. , 'Survival and apoptosis: a dysregulated balance in liver cancer ' (2007 ) 27 Liver Int. : 155 -162.

    • Search Google Scholar
  • Farazi, P. A., Glickman, J., Jiang, S. és mtsai: Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res., 2003, 63 , 5021–5027.

    Jiang S. , 'Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma ' (2003 ) 63 Cancer Res. : 5021 -5027.

    • Search Google Scholar
  • Ozturk, M., Arslan-Ergul, A., Bagislar, S. és mtsai: Senescence and immortality in hepatocellular carcinoma. Cancer Letters, 2009, 286 , 103–113.

    Bagislar S. , 'Senescence and immortality in hepatocellular carcinoma ' (2009 ) 286 Cancer Letters : 103 -113.

    • Search Google Scholar
  • Gusani, N. J., Jiang, Y., Kimchi, E. T. és mtsai: New pharmacological developments in the treatment of hepatocellular carcinoma. Drugs, 2009, 69 , 2533–2540.

    Kimchi E. T. , 'New pharmacological developments in the treatment of hepatocellular carcinoma ' (2009 ) 69 Drugs : 2533 -2540.

    • Search Google Scholar
  • Lopez, P. M., Villanueva, A., Llovet, J. M.: Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Aliment. Pharmacol. Ther., 2006, 23 , 1535–1547.

    Llovet J. M. , 'Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials ' (2006 ) 23 Aliment. Pharmacol. Ther. : 1535 -1547.

    • Search Google Scholar
  • Louafi, S., Boige, V., Ducreux, M. és mtsai: Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer, 2007, 109 , 1384–1390.

    Ducreux M. , 'Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study ' (2007 ) 109 Cancer : 1384 -1390.

    • Search Google Scholar
  • Taïeb, J., Bonyhay, L., Golli, L. és mtsai: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer, 2003, 98 , 2664–2670.

    Golli L. , 'Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules ' (2003 ) 98 Cancer : 2664 -2670.

    • Search Google Scholar
  • Yau, T., Chan, P., Epstin, R. és mtsa: Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int., 2009, 29 , 10–17.

    Epstin R. , 'Management of advanced hepatocellular carcinoma in the era of targeted therapy ' (2009 ) 29 Liver Int. : 10 -17.

    • Search Google Scholar
  • Greten, T. F., Korangy, F., Manns, M. P. és mtsa: Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer, 2009, 100 , 19–23.

    Manns M. P. , 'Molecular therapy for the treatment of hepatocellular carcinoma ' (2009 ) 100 Br. J. Cancer : 19 -23.

    • Search Google Scholar
  • Thomas, M.: Molecular targeted therapy for hepatocellular carcinoma. J. Gastroenterol., 2009, 44 , 136–141.

    Thomas M. , 'Molecular targeted therapy for hepatocellular carcinoma ' (2009 ) 44 J. Gastroenterol. : 136 -141.

    • Search Google Scholar
  • Zhu, A. X., Blaszkowszky, L. S., Ryan, D. P. és mtsai: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol., 2006, 24 , 1898–1903.

    Ryan D. P. , 'Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma ' (2006 ) 24 J. Clin. Oncol. : 1898 -1903.

    • Search Google Scholar
  • Thomas, M. B., Morris, J. S., Chadha, R. és mtsai: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol., 2009, 27 , 843–850.

    Chadha R. , 'Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma ' (2009 ) 27 J. Clin. Oncol. : 843 -850.

    • Search Google Scholar
  • Sun, W., Haller, D. G., Mykulowszky, K. és mtsai: Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocallular carcinoma (HCC): a phase II study. J. Clin. Oncol., 2007, 25 , 4574.

    Mykulowszky K. , 'Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocallular carcinoma (HCC): a phase II study ' (2007 ) 25 J. Clin. Oncol. : 4574 -.

    • Search Google Scholar
  • Siegel, A. B., Cohen, E. I., Ocean, A. és mtsai: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol., 2008, 26 , 2992–2998.

    Ocean A. , 'Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma ' (2008 ) 26 J. Clin. Oncol. : 2992 -2998.

    • Search Google Scholar
  • Koch, I., Baron, A., Roberts, S. és mtsai: Influence of hepatic dysfunction on safety, tolerability and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC). J. Clin. Oncol., 2005, 23 , 4134.

    Roberts S. , 'Influence of hepatic dysfunction on safety, tolerability and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC) ' (2005 ) 23 J. Clin. Oncol. : 4134 -.

    • Search Google Scholar
  • Pinter, M., Wichlas, M., Schmid, K. és mtsai: Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur. J. Gastroenterol. Hepatol., 2008, 20 , 1012–1019.

    Schmid K. , 'Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial ' (2008 ) 20 Eur. J. Gastroenterol. Hepatol. : 1012 -1019.

    • Search Google Scholar
  • Koeberle, D., Montemurro, M., Samaras, P. és mtsai: Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist, 2010, 15 , 285–292.

    Samaras P. , 'Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06) ' (2010 ) 15 Oncologist : 285 -292.

    • Search Google Scholar
  • Llovet, J. M., Ricci, S., Mazzaferro, V. és mtsai: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359 , 378–390.

    Mazzaferro V. , 'Sorafenib in advanced hepatocellular carcinoma ' (2008 ) 359 N. Engl. J. Med. : 378 -390.

    • Search Google Scholar
  • Dank M.: Új lehetőségek a hepatocellularis carcinoma terápiájában. LAM, 2009, 19 , 15–21.

    Dank M. , 'Új lehetőségek a hepatocellularis carcinoma terápiájában ' (2009 ) 19 LAM : 15 -21.

    • Search Google Scholar
  • Cheng, A. L., Kang, Y. K., Chen, Z. és mtsai: Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol., 2009, 10 , 25–34.

    Chen Z. , 'Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial ' (2009 ) 10 Lancet Oncol. : 25 -34.

    • Search Google Scholar
  • Bayer: Sorafenib as adjuvant treatment in the prevention of recurrence of hepatocellular carcinoma (STORM). US National Institutes of Health, Clinical Trials, gov. (online). http://www.clinicaltrials.gov

  • Hoffmann, K., Glimm, H., Radeleff, B. és mtsai: Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa. BMC Cancer, 2008, 8 , 349.

    Radeleff B. , 'Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa ' (2008 ) 8 BMC Cancer : 349 -.

    • Search Google Scholar
  • Richly, H., Schultheis, B., Adamietz, I. A. és mtsai: Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur. J. Cancer, 2009, 45 , 579–587.

    Adamietz I. A. , 'Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial ' (2009 ) 45 Eur. J. Cancer : 579 -587.

    • Search Google Scholar
  • Hsu, C. H., Shen, Y. C., Lin, Z. Z. és mtsai: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J. Hepatol., 2010, 53 , 126–131.

    Lin Z. Z. , 'Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma ' (2010 ) 53 J. Hepatol. : 126 -131.

    • Search Google Scholar
  • Berasain, C., Perugorria, M. J., Latasa, M. U. és mtsai: The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp. Biol. Med. (Maywood), 2009, 234 , 713–725.

    Latasa M. U. , 'The epidermal growth factor receptor: a link between inflammation and liver cancer ' (2009 ) 234 Exp. Biol. Med. (Maywood) : 713 -725.

    • Search Google Scholar
  • Foster, K. G., Fingar, D. C.: Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biochem. Chem., 2010, 285 , 14071–14077.

    Fingar D. C. , 'Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony ' (2010 ) 285 J. Biochem. Chem. : 14071 -14077.

    • Search Google Scholar
  • Sparks, C. A., Guertin, D. A.: Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene, 2010, 29 , 3733–3744.

    Guertin D. A. , 'Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy ' (2010 ) 29 Oncogene : 3733 -3744.

    • Search Google Scholar
  • Cseh A., Szebeni B., Szalay B. és mtsa: Akt enzim: új terápiás célpont rákban és cukorbetegségben? Orv. Hetil., 2009, 150 , 373–378.

    Szalay B. , 'Akt enzim: új terápiás célpont rákban és cukorbetegségben? ' (2009 ) 150 Orv. Hetil. : 373 -378.

    • Search Google Scholar